Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction

Toshihiko Nishimura*, Yajing Hu*, Manhong Wu, Edward Pham, Hiroshi Suemizu, Menashe Elazar, Michael Liu, Ramazan Idilman, Cihan Yurdaydin, Peter Angus, Catherine Stedman, Brian Murphy, Jeffrey Glenn, Masato Nakamura, Tatsuji Nomura, Yuan Chen, Ming Zheng, William L. Fitch, and Gary Peltz#

From the Department of Anesthesia Stanford University School of Medicine, Stanford CA 94305 (TN, YH, MW, MZ, WLF, GP); The Department of Medicine, Stanford University School of Medicine, Stanford CA 94305 (EP, ME, ML, JG); Central Institute for Experimental Animals, 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan (HS, MN, TN); and Genentech, Drug Metabolism and Pharmacokinetics, 1 DNA Way, South San Francisco, CA 94080, United States (YN); Hepatology Institute, University of Ankara, Turkey 06100 (RI, CY); Liver Transplant Unit, University of Melbourne, Austin Hospital, Heidelberg 3084, Australia (PA); Gastroenterology Department, Christchurch Hospital, and University of Otago, Christchurch, New Zealand (CS); Eiger BioPharmaceuticals, Palo Alto CA 94303 (BM).
Running Title: Chimeric Mice and Human Drug Metabolism

Address correspondence to: gpeltz@stanford.edu, 300 Pasteur Dr, Stanford, CA 94305, phone: 650 721 2487.

This manuscript contains:

37 references
4 Figures
2 tables
The text of the paper is contained on pages 4 to 16 of this submission
The number of words:

Abstract 180
Introduction 638
Discussion 749

Recommended Section Assignment: Drug Discovery and Translational Medicine

Abbreviations: AUC, area under the concentration-time curve; CYP450, cytochrome P450; DDI, drug-drug interaction; ESI, electrospray ionization; FAH, fumarylacetoacetate hydrolase; GCV, ganciclovir; LC/MS, liquid chromatography coupled with mass spectroscopy; MS/MS, tandem mass spectroscopy; TK-NOG, NOG mouse expressing a thymidine kinase transgene;
Abstract

Inter-species differences in drug metabolism have made it difficult to use pre-clinical animal testing data to predict the drug metabolites or potential drug-drug interactions (DDI) that will occur in humans. Although chimeric mice with humanized livers can produce known human metabolites for test substrates, we do not know whether chimeric mice can be used to prospectively predict human drug metabolism or a possible DDI. Therefore, we investigated whether they could provide a more predictive assessment for clemizole, a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Our results demonstrate, for the first time, that analyses performed in chimeric mice can correctly identify the predominant human drug metabolite prior to human testing. The differences in the rodent and human pathways for clemizole metabolism were of importance, since the predominant human metabolite was found to have synergistic anti-HCV activity. Moreover, studies in chimeric mice also correctly predicted that a DDI would occur in humans when clemizole was co-administered with a CYP3A4 inhibitor. These results demonstrate that using chimeric mice can improve the quality of pre-clinical drug assessment.
Introduction

Existing *in vitro* systems and *in vivo* testing in animal species have not always accurately predicted human pharmacokinetics or the human-specific drug metabolism pathways for candidate medications (Anderson et al., 2009; Leclercq et al., 2009; Walker et al., 2009). Inter-species differences in drug metabolism produce qualitative and quantitative differences between the drug metabolites produced in humans and animal species. The inability to pre-clinically identify the human-specific drug metabolites is particularly problematic; since it is most often a drug metabolite, and not the parent drug itself, that is responsible for an unexpected drug-induced toxicity (Guengerich and MacDonald, 2007; Smith and Obach, 2009). If a candidate drug has a human-specific (or more often, a human-predominant) drug metabolite, the utility of preclinical toxicity testing in animal species is quite limited (Anderson et al., 2009; Leclercq et al., 2009).

To address this problem, we (Hasegawa et al., 2011) and others (reviewed in (Yoshizato and Tateno, 2009; de Jong et al., 2010)) have developed chimeric mice, in which mouse liver is replaced by transplanted human liver cells or tissue-engineered human liver (Chen et al., 2011). In one model system, uroplasminogen activator transgene expression facilitates the growth of transplanted human liver cells (Vyse et al., 1980; Tateno et al., 2004; Meuleman et al., 2005; Azuma et al., 2007; Katoh and Yokoi, 2007); while a fumarylacetoacetate hydrolase (*Fah*) knockout mouse is used in the other system (Azuma et al., 2007) (Bissig et al., 2010). We recently produced a new model system for human liver replacement. In this new system, a herpes simplex virus type 1 thymidine kinase (*TK*) transgene was expressed within the liver of a highly immunodeficient mouse strain (*NOG*) (Ito et al., 2002) to produce the *TK-NOG* transgenic mouse (Hasegawa et al., 2011). A brief exposure to a non-toxic dose of ganciclovir (*GCV*) causes a rapid and temporally controlled ablation of mouse liver cells expressing the transgene,
which enabled the transplanted human liver cells to develop into a mature “human organ” with a 3-dimensional architecture and gene expression pattern (including many human drug metabolizing enzymes and transporters) characteristic of mature human liver. The absence of ongoing liver toxicity in the TK-NOG mice enabled the humanized liver to be stably maintained for >8 months without exogenous drug treatments. The humanized liver in chimeric TK-NOG mice was shown to express mRNAs encoding human CYP450 enzymes, transporters and transcription factors affecting drug metabolism at levels that were equivalent to those in the donor human hepatocytes. Moreover, there was extensive human CYP3A4 protein expression in the humanized livers, and chimeric TK-NOG mice could mediate human-specific drug biotransformation reactions (Hasegawa et al., 2011).

There are multiple examples where chimeric mice have been shown to produce known human-specific metabolites for several test substrates (Chen et al., 2011) (Hasegawa et al., 2011) (Tateno et al., 2004) (Katoh and Yokoi, 2007), including steroids (Katoh et al., 2007) (Lootens et al., 2009) (Pozo et al., 2009) (Kamimura et al., 2010). However, we do not know if chimeric mice can be used to predict the pattern of human drug metabolism for a candidate therapeutic prior to human clinical testing. In one recent study, chimeric mice produced mixed results when their ability to predict the pattern of human drug metabolism was assessed (De Serres et al., 2011). We also do not know if chimeric mice can be used to prospectively evaluate the potential for a DDI involving a candidate therapeutic to occur in human subjects. Since more than 30% of the US population over 57 years of age take 5 or more prescription drugs at a given time, DDIs have created major problems for patients, and for regulatory authorities (Zhang et al., 2010). However, using available in vitro or in vivo animal models, it has been difficult to predict many of the clinically important DDIs, which only became apparent after drug development was completed (Bode, 2010). Therefore, we investigated whether TK-NOG mice with ‘humanized livers’ could provide more predictive information about the human metabolic pathways and
metabolites for a candidate therapeutic, which is being developed as a novel treatment for HCV infection. Clemizole, an antihistamine drug that was once widely used for treatment of allergic disease, was recently discovered to be a potent inhibitor (IC50 24 nM) of the interaction between a HCV protein (NS4B) and HCV RNA (Einav et al., 2008). Although clemizole was widely utilized in the 1950’s and 1960’s, this was before contemporary regulatory requirements were established for new drug development, and we have very minimal information about its pharmacokinetics and metabolism.

Methods

Chemicals and reagents. For in vitro and animal experiments, clemizole hydrochloride and omeprazole were purchased from Sigma (St. Louis, MO); ritonavir was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Pooled Human liver microsomes, male rat and mouse liver microsomes were purchased from BD Gentest (Woburn, MA). Cryopreserved human hepatocytes and recombinant CYP450 enzymes were purchased from BD Biosciences (San Jose, CA, USA). Rat hepatocytes were freshly isolated according to standard procedures. All other chemicals were purchased from commercial sources and were of the highest purity available. Boceprevir was a gift from Leslie Holsinger (Virobay).

Mouse pharmacokinetic studies. All animal experiments were performed using protocols approved by the Stanford Institutional Animal Care and Use Committee. Male C57BL6/J and Balb/c mice (8 weeks of age) were obtained from Jackson Labs and housed for 2 weeks prior to experimentation. NOG mice were obtained from In Vivo Sciences International (Sunnyvale, CA). Chimeric TK-NOG mice with humanized livers were prepared as described (Hasegawa et al., 2011), except the GCV dose was increased to 25 mg/kg, which was administered 7 and 5 days prior to human liver cell transplantation. The human albumin levels were determined using
previously described methods, and the human albumin concentration was shown to correlate with the extent of liver humanization (Hasegawa et al., 2011). The pharmacokinetic studies using these mice were performed 8-12 weeks after transplantation of human liver cells. Eight control NOG mice and eight humanized TK-NOG mice were administered 25 mg/kg clemizole PO, and blood samples were collected 30 minutes after dosing. The C57BL/6J mice (3 per time point) were dosed with 25 mg/kg PO Clemizole, and blood samples were collected at 15, 30 min and 1, 2, 4 and 6 hrs after dosing for analysis. For the DDI studies, eight humanized TK-NOG mice were dosed with Clemizole (25 mg/kg P.O.) with or without ritonavir (20 mg/kg P.O.), and blood samples were collected 30 minutes after dosing. Six of these mice were also treated with debrisoquine (10 mg/kg PO), in the presence or absence of ritonavir (20 mg/kg PO), and plasma obtained 2 hr later for analysis.

Quantitative analysis of clemizole and metabolites in plasma. Mouse plasma (50 uL) was treated with acetonitrile with 0.1% formic acid (200 uL), vortexed and incubated at -20 °C for one hour, centrifuged at 10,000 rpm for 10 min. The supernatants were collected, dried and re-suspended in 50uL 5% acetonitrile with 0.1% formic acid for the analysis by LC/MS. HPLC was performed using an Agilent 1200 column compartment, capillary pump, and an autosampler on a Zorbax C18 column, 0.5x150 mm. The flow rate was 20 mL/min with a gradient from 5% solvent B (acetonitrile with 0.1% formic acid; solvent A is 0.1% formic acid in water) to 95% B in 30 min and held at 95% B for 5 min. Mass spectrometric analysis were carried out on an Agilent Model 6520 qTOF mass spectrometer equipped with an ESI source. The heated capillary temperature in the source was held at 325°C. Full scan (m/z 110–1000) spectra or data dependent MS/MS spectra were collected. The metabolites were identified based on their collision-induced dissociation behavior in tandem mass spectrometry, accurate mass and retention time. Quantitative analysis of clemizole was performed using a calibration curve at 9-1257 ng/ml clemizole spiked into blank mouse plasma and extracted as above. An internal
standard 1-(p-bromobenzyl)-2-(1-pyrrolidinylmethyl)-Benzimidazole was also spiked in at 1000ng/ml. Relative amounts of clemizole and metabolites in each sample were calculated using the assumption that all compounds had the same MS response factor.

**Statistical analysis.** To assess the statistical significance of the differences in the relative amount of clemizole and its metabolites (M1, M2, M6, M12, M14 and M15) measured in plasma obtained from control and humanized TK-NOG mice (Table 1), or between control and ritonavir treated mice, a two-sample two-sided t test was used.

**Human pharmacokinetic and metabolite studies.** Phase 1b studies (to be reported elsewhere) were conducted in genotypes 1 and 2 HCV patients under IRB-approved protocols to investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of clemizole HCl (see www.ClinicalTrials.gov and approval by the University of Ankara Medical School Ethics Committee; study sponsor Eiger BioPharmaceuticals, Inc.). De-identified aliquots of excess material, which were not needed for clinical monitoring, were kindly provided by Wenjin Yang (Eiger BioPharmaceuticals, Inc.) to us for PK and metabolite analysis. The samples obtained were from human subjects that were administered 100 mg Clemizole P.O., with or without 100 mg ritonavir P.O. administered one hour before the clemizole, and blood samples were obtained 0 to 12 hrs after dosing. The relative abundance of clemizole and its metabolites in plasma were measured in samples obtained from 10 patients treated with clemizole alone, and from 3 patients who participated in the subcomponent evaluating the effect of ritonavir co-administration, by LC/MS analysis as described below.

**In vitro HCV replication assay.** The plasmid FL-J6/JFH-5’C19Rluc2AUbi, which consists of the full-length HCV genome and expresses the *Renilla* luciferase (Tscherne et al., 2006), was a gift from Charles M. Rice. In vitro transcription of HCV RNA was performed as described with minor
modifications (Einav et al., 2010). Briefly, Huh 7.5 cells were maintained in DMEM (Gibco) supplemented with 1% L-glutamine (Gibco), 1% penicillin, 1% streptomycin (Gibco), 1x nonessential amino acids (Gibco) and 10% FBS (Omega Scientific). Electroporation was performed by mixing 5 µg of RNA with 400 µL of ice-cold PBS containing washed Huh 7.5 cells at a density of 1.5 x 10^7 cells/mL. The mixture was immediately pulsed (0.82 kV, five 99 µs pulses) with a BTX-830 electroporator. After a 10 min recovery at 25 °C, pulsed cells were diluted into 10 ml of pre-warmed growth medium. Cells were passaged, their luciferase activity verified, and seeded in 96-well plates (2 x 10^4 cells/well) 1 day prior to addition of the inhibitory compounds. Cells were grown in 3 replicates in the presence of serial dilutions of the inhibitory compounds. Untreated cells with or without corresponding concentrations of DMSO were used as negative controls. 48 hour after treatment with the inhibitory compounds, cells were subjected to Alamar Blue-based viability assays and luciferase assays.

**Viability Assay and Luciferase Assay.** Cell viability was assessed by incubation with 10% Alamar Blue Reagent (Invitrogen) for 2 hours, the absorbance was measured at 570 nm and 630 nm with a plate reader (TECAN M1000), and viability is determined by comparing the \( A_{570} - A_{630} \). Luciferase activity was measured using the *Renilla* luciferase kit (Promega) after assessing cell viability. The cells were washed with ice-cold PBS and lysed with 20 µL of ice-cold *Renilla* lysis buffer (Promega). We injected 40 µL of the *Renilla* luciferase assay buffer containing assay substrate and measured luciferase activity with a 4 sec integration using a plate reader. All experiments were done at least four times, and at least 3 replicates were performed each time.

**Analysis of the drug synergy data.** The in vitro drug efficacy data were analyzed using the The MacSynergy II program (kindly provided by M. N. Prichard) according to the Bliss independence model (Pritchard et al., 1992) (Prichard and Shipman, 1990). The effect of a drug
combination is determined by subtracting the experimental values from theoretical additive values (Pritchard et al., 1992). A 3-dimensional differential surface plot is used to evaluate the interaction between the tested drugs. Synergy is indicated if the plot peaks above a theoretical additive plane, and antagonism is indicated if depressions are formed below this plane (Prichard and Shipman, 1990). The data sets with 4 replicates were assessed at the 95% confidence level for each experiment (Pritchard et al., 1992) (Prichard and Shipman, 1990) (Prichard and Shipman, 1996). Synergy (volume under the curve) and log volume were calculated. As suggested (Pritchard et al., 1992), these data sets are interpreted according to the follow rules: volumes of synergy or antagonism at values of <25 µM²% are insignificant, 25–50 µM²% are minor but significant, 50–100 µM²% are moderate and probably important in vivo, and >100 µM²% are strong and likely to be important in vivo.

Results

We first examined clemizole's pharmacokinetic profile in a commonly used, conventional mouse strain. Clemizole had an un-expectedly short plasma half-life (measured at 0.15 hr); it was very rapidly biotransformed into a glucuronide (M14) and a dealkylated metabolite (M12), and into a variety of lesser metabolites in C57BL/6J mice (Figure 1). Although we previously demonstrated that the pattern of metabolism for several drugs could differ among inbred strains (Guo et al., 2006; Guo et al., 2007), two other inbred strains exhibited the same ultra-rapid rate of clemizole metabolism and produced the same metabolites as C57BL/6J mice (Supplemental Figure 1). Then, the pattern of clemizole metabolism in TK-NOG mice with 'humanized livers' was compared with that in control mice with the same genetic background. Based upon the human albumin concentration (range 1.3 to 7.0 mg/ml) in their sera, the extent of liver humanization ranged from 13-70%. The relative amount of clemizole and 6 metabolites in plasma 30 min after administration of a single (25 mg/kg PO) dose of clemizole was measured.
(Table I). The relative amounts of 3 metabolites did not significantly differ between control and humanized mice (p>0.3). However, 'humanized' TK-NOG mice had a substantially larger amount of metabolite M1 in their plasma (2.2 fold, p<0.0004); along with a significantly increased level of M6 (1.5 fold, p<0.049), and a decreased amount of M14 (0.68 fold, p<0.046) in their plasma. Since these livers were only partially humanized, the remnant murine liver was also rapidly metabolizing this drug. However, by focusing on the differences in the drug metabolites that were produced by the humanized and conventional murine livers, drug metabolites that will predominate in humans could be identified. This data indicated that M1 and M6 could be important metabolites in humans, and that clemizole metabolism in humans and mice could differ.

After the murine studies were completed, plasma samples were obtained from ten human subjects after administration of a single (100 mg P.O.) dose of clemizole (Figure 1). Clemizole had a much longer plasma half-life (measured at 3.4 hrs) in humans, and a very different pattern of drug metabolites relative to mice. Clemizole was rapidly converted to a single major metabolite (M1), which accounted for 55% of all drug and metabolites present in human plasma. The area under the concentration time curve (AUC) (0-24 hr) is calculated to assess the relative level of drug or metabolite exposure over time. Comparison of the AUCs (0-24 hr) calculated for each metabolite indicates that mice and humans have very different levels of exposure to the major drug metabolites (Table 2). While M1 and M6 account for 77% of human drug metabolite exposure; they account for only 6% of murine drug metabolite exposure. In contrast, M12 and M14 account for 77% of mouse drug metabolite exposure, but only 2% of human metabolite exposure. The human metabolic profile was consistent with that observed in the humanized mice, which had indicated that the pathways mediating M1 and M6 production would be important.
Clemizole metabolism in rodents and humans. A detailed *in vitro* characterization of the pathways for clemizole metabolism in rodents and humans was performed as described in the supplement (Supplemental Figures 2-3 and Supplemental Tables 1-3), and the inter-species differences are summarized in Figure 1B. In human liver, clemizole is primarily converted an intermediate A, which can be oxidized by several CYP450 enzymes (CYP3A4, CYP2C19 or CYP2D6) to M1. CYP3A4, which is the most abundantly expressed CYP450 enzyme in human liver, mediates the majority of this drug biotransformation reaction. The role of CYP3A4 is confirmed by the ability of ritonavir, which is an inhibitor of CYP3A4 activity, to inhibit clemizole metabolism *in vitro* (Figure S4). In contrast, a different type (CYP2C-like) of aromatic oxidation reaction produces the rodent-predominant metabolites (M12, M14 and M15), which is the dominant pathway for clemizole metabolism in rodent liver.

Predicting a human DDI. We wanted to determine if studies using humanized TK-NOG mice could prospectively predict whether a potential DDI involving clemizole would occur. Ritonavir is a CYP3A4 inhibitor, that has been co-administered with other drugs to increase their duration of action (Hsu et al., 1998). Given the identified pathways for clemizole metabolism in human liver, it was possible that ritonavir-mediated inhibition of CYP3A4 could alter clemizole pharmacokinetics. We hypothesized that if a DDI of this type occurred in the humanized mice, a similar type of DDI would be observed in human patients. Therefore, clemizole was administered to eight humanized TK-NOG mice with or without ritonavir co-administration, and clemizole metabolites were analyzed in plasma samples. Ritonavir co-administration decreased the amount of the human-predominant clemizole metabolites (M1 and M6, p<0.005) (Figure 2). The concentration of M12, a mouse predominant metabolite was also decreased by ritonavir co-administration, while the concentrations of two other metabolites (M14 and M15) that are produced by a mouse-specific biotransformation reaction were not altered. We have previously demonstrated that chimeric TK-NOG mice can metabolize debrisoquine to 4-OH-debrisoquine,
which is a human predominant route of drug metabolism that is catalyzed by CYP2D6 (Hasegawa et al., 2011). Ritonavir co-administration did not alter the CYP2D6-mediated conversion of debrisoquine to 4-OH debrisoquine in 6 humanized TK-NOG mice analyzed (p-value>0.5) (Figure 2). These results demonstrate that ritonavir co-administration specifically decreased the production of human CYP3A4-specific metabolites of clemizole, and indicate that a DDI could occur if ritonavir was co-administered with clemizole in human subjects.

Since increasing the time that an HCV-infected individual maintains an effective plasma clemizole concentration could have a therapeutic benefit, a pilot clinical study was performed to determine if ritonavir co-administration would increase plasma clemizole levels after dosing. Three HCV infected individuals were treated with clemizole (100 mg PO) alone, and on a separate day with clemizole (100 mg PO) and ritonavir (100 mg PO, one hour before clemizole administration). The plasma clemizole concentration was measured over a 12 hr period following both treatments. Ritonavir co-administration increased the AUC(0-12 hr) for clemizole in all 3 treated individuals (by 22, 38 and 89%, respectively) (Figure 3). Although ritonavir co-administration had a limited effect in the first patient, ritonavir co-administration substantially increased the Cmax and AUC for clemizole in patients 2 and 3. Thus, the humanized TK-NOG mouse results correctly predicted that a DDI would occur between ritonavir and clemizole, and this could be exploited to improve the efficacy of clemizole treatment for HCV infection.

Clemizole M1 metabolite has anti-viral activity. Since high levels of M1 were present in human plasma, it was of importance to determine whether this metabolite had anti-viral activity. Clemizole has recently been shown to have a synergistic inhibitory effect on HCV replication in vitro when combined with protease inhibitors (Einav et al., 2010). Therefore, the effect of the M1 metabolite, either alone or in combination with a protease inhibitor (boceprevir) that was recently approved for treatment of HCV (Bacon et al., 2011) (Poordad et al., 2011), was measured using
an *in vitro* luciferase reporter-linked HCV replication assay. When M1 was combined with boceprevir, their combined antiviral effect in this assay was significantly more potent than the theoretical additive effects of either drug alone (*Figure 4*). The calculated synergy volume was 101 µM^2%; which (according the established criteria (Pritchard et al., 1992)) is indicative of strong synergy that is likely to be important *in vivo*. There was no evidence of antiviral antagonism at any of the tested doses; and no cellular toxicity was noted after incubation with either drug alone, nor was cytotoxicity increased after exposure to the drug combinations. Thus, the observed synergy between boceprevir and M1 is specific, and it does not reflect a synergistic toxicity arising from the drug combination. Although the level of synergy observed with M1 was less than that obtained with clemizole (synergy volume 230 µM^2%) (*Figure 4*), these results indicate that clemizole’s major metabolite has significant anti-viral activity.

**Discussion**

Differences between the rodent and human pathways used for metabolism of a candidate medication are not rare, which is why animal testing results have not always accurately predicted human pharmacokinetic parameters or the drug metabolism pathways for a candidate medication (Anderson et al., 2009; Leclercq et al., 2009; Walker et al., 2009). Similarly, the results from *in vitro* analyses using human hepatocytes or microsomal preparations have correctly predicted the *in vivo* human metabolite profile for about half (46-65%) of the 48 tested compounds (Dalvie et al., 2009). This study indicates how the use of humanized TK-NOG mice can enable human-predominant drug metabolites to be identified prior to human drug exposure. Although chimeric mice have both human and murine liver tissue, human drug metabolites could be predicted by identifying the differentially abundant metabolites produced in chimeric mice (relative to conventional mice). However, the variable extent of liver humanization (13-70%) (*Supplemental Table 4*) in the chimeric mice analyzed here could complicate the analysis.
of other drugs; especially when the pathways for murine and human drug metabolism are not as divergent as in the case examined here. The remaining mouse liver could produce metabolites that could confound toxicologic analyses performed with these chimeric mice. Therefore, methods are being developed to increase the extent of liver humanization that is obtained with this model system, which should improve the results obtained using humanized TK-NOG mice. Since three different inbred strains produced the same pattern of clemizole metabolites, there is a common murine (strain-independent) pattern of clemizole metabolism, which differs from the pathways used in humans. The inter-species differences in clemizole metabolism highlight the difficulties in using data obtained from conventional rodent species to predict human drug metabolism, and consequently, potential drug-induced toxicity. For clemizole, if toxicities were caused by the human predominant metabolite M1, toxicology testing in rodents would provide a false assurance of drug safety. Similarly, rodent testing could raise a false drug safety concern if a rodent-predominant (M12, M14) metabolite or reactive intermediate B caused toxicity. Although some form of human testing is always required for assessment of a candidate drug, the information obtained from analyses performed in chimeric mice prior to human testing can be quite informative. The identified differences between the rodent and human pathways for clemizole metabolism assume an increased importance, since the major human clemizole metabolite had synergistic anti-HCV activity in vitro, which could extend the anti-viral activity of clemizole when administered in combination with the recently approved HCV protease inhibitors. As demonstrated here, analyses in chimeric mice can reveal whether pre-clinical toxicity testing in animal species has adequately covered the metabolites that will be formed in humans. Although the interaction of ritonavir and clemizole provides a straightforward example, this study also demonstrates how chimeric mice can be used to assess whether a potential DDI is likely to occur.

Our analysis indicates that CYP3A4 plays a major role in clemizole metabolism. We previously
demonstrated that there was abundant human CYP3A4 protein expression in the livers of chimeric TK-NOG mice (Hasegawa et al., 2011). Although the effect that genetic differences in CYP3A enzymes have on clemizole metabolism remains to be determined, any compound that is metabolized by CYP3A4 is usually also a CYP3A5 substrate. However, the high frequency of inactivating CYP3A5*3 alleles in Caucasians (up to 90%) and Asians (up to 80%) makes it likely that CYP3A5 may have a lesser role in clemizole metabolism (Lamba et al., 2002) (Xie et al., 2004). It is more likely that inter-individual variability in CYP3A4 expression is responsible for the variable affect of ritonavir on the pharmacokinetic profiles in these 3 randomly selected Caucasian individuals.

Consistent with the results obtained from analysis of other drugs (Dalvie et al., 2009), the data in Table 2 indicates that the in vitro results (microsomes or hepatocytes) did not correctly predict the in vivo profile of clemizole metabolism. Since the rodent in vitro systems could not even predict how clemizole would be metabolized in vivo in rodents, it would have been very difficult to use human in vitro data to predict the clemizole metabolites that would be produced in human subjects. However, there are limiting factors affecting the use of these chimeric mice for human-specific pharmacokinetic and toxicologic studies. (i) These mice cannot be used to analyze immune-mediated drug toxicities because they are immunocompromised. (ii) They cannot be used to identify extra-hepatic human-specific factors affecting drug metabolism or clearance. (iii) Since we do not know the extent of biliary tract humanization in these chimeric mice, we do not know if they can be used to predict the clearance of drugs in humans that depend upon human-specific transporter-mediated hepatobiliary clearance. Until we know the extent of biliary tract humanization, we do not know whether the potential for drugs [e.g. bosentan (Fattinger et al., 2001)] to cause cholestatic liver toxicity in humans can be evaluated in these mice. Despite these limitations, this example demonstrates how the use of humanized mice can enhance our ability to predict human drug metabolism and the occurrence of a DDI for...
a candidate medication. As has occurred with other medications (Hsu et al., 1998), ritonavir co-
administration could be used to increase the anti-HCV efficacy of clemizole. Although this is
only one example, it indicates that it is likely that the use of chimeric mice could improve the
quality of pre-clinical drug assessment.

Acknowledgements

We thank Wenjin Yang and Eiger BioPharmaceuticals, Inc. for providing the clinical samples
used in this study.

Author Contributions

Performed experiments: Nishimura, Hu, Suemizu, Wu, Elazar, Liu, Idilman, Yurdaydin, Angus,
Stedman and Murphy
Wrote Paper: Hu, Peltz, Glenn
Data Analysis: Zheng, Fitch
Designed experiments: Nakamura, Nomura and Chen
Participated in the design of the studies: Glenn, Peltz
References


Pritchard MN, Prichard LE and Shipman C, Jr. (1992) MacSynergy II version 1.0 user’s manual, in, University of Michigan, Ann Arbor.


Footnotes

a This work was supported by a Transformative RO1 award from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases to G.P [1R01DK090992-01]. J.G and B.M were partially supported by an award from the National Institutes of Health National Institute Allergy and Infectious Diseases [R42 AI088793].

*These authors contributed equally to this work

# Address reprint requests to: Gary Peltz, Stanford University School of Medicine 300 Pasteur Drive L232 Stanford CA 94305; gpeltz@stanford.edu

Disclosure

One author (JG) has an equity interest in, and three authors (JG, GP, BM) are consultants for Eiger BioPharmaceuticals and/or Eiger Group International, which are developing clemizole for HCV treatment.
Figure Legends

Figure 1. (A) Clemizole metabolism in mice and humans. The top graphs show the measured plasma clemizole concentration at the indicated times after a single oral dose of clemizole was administered to three C57BL/6 mice (25 mg/kg) or 10 human subjects (100 mg). While clemizole was rapidly metabolized in mice (measured half-life 0.15 hr), its measured half-life in humans was 3.4 hr. The bottom graphs show the relative normalized abundance of clemizole and metabolites in plasma at the indicated time after dosing. In mice, clemizole was rapidly metabolized to 2 major (M12 and M14) metabolites, but only minimal amounts of M1 or M6 were produced; while in humans, clemizole was converted to two predominant metabolites (M1 and M6). (B) The structure of clemizole and the pathways for production of its metabolites are shown. In humans, clemizole is converted to intermediate ‘A’ by any of a number of CYP450s. Then, CYP3A4, CYP2C19 and CYP2D6 can further oxidize this intermediate to M1; while in the presence of CYP2C9 or CYP1A2, M2 is generated, but they cannot produce M1. Cyp2C9 appears to be the only source of M4, which is a minor metabolite in humans. The structures of the major human (M1, M6) and rodent (M12, M14) plasma metabolites are highlighted.

Figure 2. Top panel: Six humanized TK-NOG mice were first dosed with clemizole alone (25 mg/kg PO), and then with clemizole (25 mg/kg PO) and ritonavir (20 mg/kg PO). The amount of 6 different clemizole metabolites in plasma was measured at 30 minutes after dosing. The plasma concentrations of the human-predominant M1 and M6 metabolites were significantly decreased by ritonavir co-administration, as were the concentrations of M2 and M12, while that of M14 and M15 was unchanged. Bottom panel: Five humanized TK-NOG mice were first dosed with debrisoquine alone (10 mg/kg PO), and then with Debrisoquine (10 mg/kg PO) and ritonavir (20 mg/kg PO). The amount of its main metabolite, 4-OH-debrisoquine was measured in plasma 2 hrs after dosing. The relative amount of 4-OH debrisoquine was not significantly
changed by ritonavir co-administration.

**Figure 3.** Three HCV infected individuals were first administered clemizole alone (100 mg PO), and then with clemizole (100 mg PO) and ritonavir (100 mg PO BID). The amount of clemizole in the plasma was measured over a 12 hr period after dosing.

**Figure 4.** Differential surface plot of the synergistic anti-HCV effect of boceprevir with either clemizole (top) or the M1 metabolite of clemizole (bottom). The 3-dimensional plot represents the differences between the actual anti-viral effects and the theoretical additive effects at the indicated concentrations for the 2 compounds tested. Only statistically significant (95% CI) differences between the 2 compounds were considered at any given concentration. Peaks above the theoretical additive plane indicate synergy, whereas depressions below it indicate antagonism. The colors indicate the level of synergy or antagonism. Both clemizole and the M1 metabolite exhibit a substantial synergistic anti-viral effect with boceprevir.
Table 1. Clemizole (25 mg/kg PO) was administered to eight control NOG mice (C1-8) and eight TK-NOG mice with ‘humanized livers’ (Hu m1-8). The relative amounts of 6 metabolites and clemizole in plasma 30 min after dosing were measured. This table shows the human serum albumin (hAlb) concentration (mg/ml) in the humanized liver TK-NOG mice, and the relative abundances of clemizole metabolites in plasma. The ratio indicates the average amount of each metabolite in humanized TK-NOG mice divided by that in control mice. Although both groups had equivalent relative amounts of 3 metabolites (p-value>0.3), the ‘humanized’ mice had a significantly increased relative amount of the M1 and M6 metabolites, and a significantly decreased relative amount of M14.

<table>
<thead>
<tr>
<th></th>
<th>hAlb</th>
<th>Clem</th>
<th>M1</th>
<th>M2</th>
<th>M6</th>
<th>M12</th>
<th>M14</th>
<th>M15</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>4.1</td>
<td>4.1</td>
<td>10.4</td>
<td>14.1</td>
<td>28.3</td>
<td>37.5</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>C2</td>
<td>5.5</td>
<td>3.2</td>
<td>8.1</td>
<td>12.9</td>
<td>37.9</td>
<td>31.2</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>C3</td>
<td>6.8</td>
<td>2.3</td>
<td>3.3</td>
<td>8</td>
<td>24</td>
<td>50.6</td>
<td>4.8</td>
<td></td>
</tr>
<tr>
<td>C4</td>
<td>3.1</td>
<td>3.1</td>
<td>8</td>
<td>9.3</td>
<td>20.5</td>
<td>39.3</td>
<td>16.7</td>
<td></td>
</tr>
<tr>
<td>C5</td>
<td>2.8</td>
<td>8</td>
<td>5.7</td>
<td>12.1</td>
<td>27.5</td>
<td>33.3</td>
<td>10.7</td>
<td></td>
</tr>
<tr>
<td>C6</td>
<td>6.03</td>
<td>5.49</td>
<td>20.0</td>
<td>10.19</td>
<td>28.78</td>
<td>28.50</td>
<td>1.01</td>
<td></td>
</tr>
<tr>
<td>C7</td>
<td>3.81</td>
<td>1.79</td>
<td>6.52</td>
<td>12.17</td>
<td>27.04</td>
<td>47.22</td>
<td>1.46</td>
<td></td>
</tr>
<tr>
<td>C8</td>
<td>4.53</td>
<td>6.43</td>
<td>11.38</td>
<td>10.17</td>
<td>25.76</td>
<td>40.71</td>
<td>1.02</td>
<td></td>
</tr>
<tr>
<td>Hu m1</td>
<td>4.2</td>
<td>1.8</td>
<td>8.9</td>
<td>13.6</td>
<td>8.3</td>
<td>20.6</td>
<td>39.8</td>
<td>6.9</td>
</tr>
<tr>
<td>Hu m2</td>
<td>1.5</td>
<td>4.4</td>
<td>7.1</td>
<td>8.3</td>
<td>13</td>
<td>29.6</td>
<td>35.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Hu m3</td>
<td>1.6</td>
<td>5.3</td>
<td>7.9</td>
<td>9.2</td>
<td>16.8</td>
<td>32.1</td>
<td>26.9</td>
<td>1.8</td>
</tr>
<tr>
<td>Hu m4</td>
<td>2.2</td>
<td>4.3</td>
<td>7.1</td>
<td>14.2</td>
<td>5.9</td>
<td>14.8</td>
<td>48.5</td>
<td>5.2</td>
</tr>
<tr>
<td>Hu m5</td>
<td>2.7</td>
<td>3.6</td>
<td>13.1</td>
<td>10</td>
<td>26</td>
<td>29</td>
<td>16.5</td>
<td>1.8</td>
</tr>
<tr>
<td>Hu m6</td>
<td>1.3</td>
<td>6.25</td>
<td>12.25</td>
<td>18.24</td>
<td>23.10</td>
<td>26.37</td>
<td>12.33</td>
<td>1.46</td>
</tr>
<tr>
<td>Hu m7</td>
<td>7</td>
<td>8.75</td>
<td>10.73</td>
<td>18.66</td>
<td>21.30</td>
<td>28.86</td>
<td>9.59</td>
<td>2.12</td>
</tr>
<tr>
<td>Hu m8</td>
<td>1.6</td>
<td>7.02</td>
<td>9.04</td>
<td>13.59</td>
<td>19.92</td>
<td>28.77</td>
<td>20.69</td>
<td>0.97</td>
</tr>
</tbody>
</table>

Ratio 1.13 2.21 1.44 1.51 0.96 0.68 0.59
p-value 0.526 0.0004 0.095 0.049 0.659 0.046 0.389
Table 2. The AUC (0-24 hr) for exposure to clemizole and the major in vivo metabolites were calculated for C57BL/6 mice and for human subjects using the data presented in Figure 1. For comparison with the in vitro results, the % of the total identified metabolites present after clemizole was incubated with human, rat or mouse microsomes for 1 hr, or after incubation with rat or human hepatocytes for 30 minutes are shown.

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>% Total AUC</th>
<th>Microsomes</th>
<th>Hepatocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Human</td>
<td>Mouse</td>
<td>Rat</td>
</tr>
<tr>
<td>Clemizole</td>
<td>8.8</td>
<td>1.3</td>
<td>40</td>
</tr>
<tr>
<td>M1</td>
<td>54.9</td>
<td>4.7</td>
<td>35</td>
</tr>
<tr>
<td>M2</td>
<td>1.1</td>
<td>5.6</td>
<td>2</td>
</tr>
<tr>
<td>M4</td>
<td>1.1</td>
<td>2.9</td>
<td>5</td>
</tr>
<tr>
<td>M6</td>
<td>22.0</td>
<td>2.4</td>
<td>2</td>
</tr>
<tr>
<td>M9</td>
<td>8.8</td>
<td>0.3</td>
<td>3</td>
</tr>
<tr>
<td>M12</td>
<td>1.1</td>
<td>21.2</td>
<td>0.6</td>
</tr>
<tr>
<td>M14</td>
<td>1.1</td>
<td>55.8</td>
<td>0</td>
</tr>
<tr>
<td>M15</td>
<td>1.1</td>
<td>5.9</td>
<td>0</td>
</tr>
</tbody>
</table>
C57B6 Mice

Human Subjects

Fig 1A

This article has not been copyedited and formatted. The final version may differ from this version.
This article has not been copyedited and formatted. The final version may differ from this version.
Fig 3

This article has not been copyedited and formatted. The final version may differ from this version.
Fig 4